Clinical trial
Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ…
NCT00324298 · Queen Mary University of London, Other · Completed
Key facts
| NCT number | NCT00324298 |
|---|---|
| Title | Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles |
| Official title | A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3 |
| Lead sponsor | Queen Mary University of London, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Testicular Germ Cell Tumor |
| Intervention type | Biological, Drug, Procedure |
| Interventions | bleomycin sulfate, cisplatin, etoposide, management of therapy complications |
| Enrollment | 210 |
| Start date | Jul 1, 2003 |
| Completion | Mar 1, 2011 |
| First posted | May 11, 2006 |
| Last update posted | Aug 12, 2013 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: